Schroder Investment Management Group Arcus Biosciences, Inc. Transaction History

Schroder Investment Management Group

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$16.97 - $22.03 $4.24 Million - $5.5 Million	-249,579 Reduced 94.16%	15,485 $314,000
Q1 2023 May 11, 2023	BUY	$15.96 - $23.15 $2.38 Million - $3.45 Million	148,932 Added 128.24%	265,064 $4.83 Million
Q4 2022 Feb 10, 2023	SELL	$19.7 - $35.71 $27,777 - $50,351	-1,410 Reduced 1.2%	116,132 $2.4 Million
Q3 2022 Nov 10, 2022	BUY	$23.23 - $30.07 $2.06 Million - $2.67 Million	88,849 Added 309.65%	117,542 $3.08 Million
Q2 2022 Aug 11, 2022	BUY	$17.23 - $37.73 $494,380 - $1.08 Million	28,693 New	28,693 $700,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

Stay updated on Schroder Investment Management Group with notifications on news.